Secondary Hyperparathyroidism Clinical Trials

10 recruitingLast updated: June 18, 2026

There are 10 actively recruiting secondary hyperparathyroidism clinical trials across 23 countries. Studies span Phase 3, Not Applicable, Phase 1, Phase 2. Top locations include St Louis, Missouri, United States, Paris, France, Bron, France. Updated daily from ClinicalTrials.gov.


Secondary Hyperparathyroidism Trials at a Glance

10 actively recruiting trials for secondary hyperparathyroidism are listed on ClinicalTrialsFinder across 6 cities in 23 countries. The largest study group is Phase 3 with 3 trials, with the heaviest enrollment activity in St Louis, Paris, and Bron. Lead sponsors running secondary hyperparathyroidism studies include Shaanxi Micot Pharmaceutical Technology Co., Ltd., Amgen, and Hospices Civils de Lyon.

Browse secondary hyperparathyroidism trials by phase

Treatments under study

About Secondary Hyperparathyroidism Clinical Trials

Looking for clinical trials for Secondary Hyperparathyroidism? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Secondary Hyperparathyroidism trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Secondary Hyperparathyroidism clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting

Precision Medicine Approaches to Renal Osteodystrophy

Chronic Kidney DiseasesCkd-MbdSecondary Hyperparathyroidism+2 more
Thomas Nickolas40 enrolled1 locationNCT05880914
Recruiting

Calcium Isotope Ratios to Assess Calcium Bone Balance in Dialysis Children Receiving Cinacalcet

Children Over 3 Undergoing Dialysis With Secondary Hyperparathyroidism
Hospices Civils de Lyon20 enrolled7 locationsNCT07007338
Recruiting

Parathyroid Tumor Clonal Status

Primary HyperparathyroidismParathyroid TumorSecondary Hyperparathyroidism (SHPT)+1 more
Washington University School of Medicine839 enrolled1 locationNCT05997810
Recruiting
Phase 3

A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

Secondary Hyperparathyroidism
Amgen24 enrolled23 locationsNCT03969329
Recruiting
Phase 3

A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

Chronic Kidney DiseaseSecondary Hyperparathyroidism
Amgen56 enrolled43 locationsNCT03633708
Recruiting
Phase 1

A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism

Hemodialysis Subjects With Secondary Hyperparathyroidism
Shaanxi Micot Pharmaceutical Technology Co., Ltd.6 enrolled1 locationNCT07284043
Recruiting
Phase 3

Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism

Secondary Hyperparathyroidism, Chronic Kidney Disease
Shaanxi Micot Pharmaceutical Technology Co., Ltd.424 enrolled1 locationNCT07122401
Recruiting
Phase 2

Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis

Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Shaanxi Micot Pharmaceutical Technology Co., Ltd.310 enrolled1 locationNCT06976177
Recruiting

A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.

Chronic Kidney Disease 5DSecondary Hyperparathyroidism
Boryung Pharmaceutical Co., Ltd1,000 enrolled1 locationNCT06126016
Recruiting
Not Applicable

Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism

Secondary Hyperparathyroidism;Parathyroidectomy
The Second Hospital of Nanjing Medical University200 enrolled1 locationNCT04922892